Sio Capital Management, LLC Aeglea Bio Therapeutics, Inc. Transaction History

Sio Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.35 - $1.54 $582,251 - $2.56 Million	-1,663,577 Reduced 35.63%	3,004,959 $1.35 Million
Q2 2022 Aug 15, 2022	BUY	$0.5 - $2.66 $1.9 Million - $10.1 Million	3,797,435 Added 435.94%	4,668,536 $2.36 Million
Q1 2022 May 16, 2022	BUY	$1.87 - $4.77 $696,763 - $1.78 Million	372,601 Added 74.74%	871,101 $2 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $183,750 - $442,050	52,500 Added 11.77%	498,500 $2.37 Million
Q3 2021 Nov 15, 2021	BUY	$6.03 - $7.95 $261,382 - $344,608	43,347 Added 10.77%	446,000 $3.55 Million
Q1 2021 May 14, 2021	BUY	$6.76 - $8.57 $1.43 Million - $1.81 Million	211,549 Added 110.7%	402,653 $3.19 Million
Q4 2020 Feb 16, 2021	SELL	$7.02 - $9.83 $140,400 - $196,600	-20,000 Reduced 9.47%	191,104 $1.5 Million
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $846,527 - $2.33 Million	211,104 New	211,104 $1.95 Million
Q4 2017 Feb 14, 2018	SELL	$4.0 - $5.98 $518,332 - $774,906	-129,583 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$2.91 - $4.93 $377,086 - $638,844	129,583	129,583 $639,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Sio Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sio Capital Management, LLC with notifications on news.